Adrian M. Senderowicz
Radiation Biology Branch
National Cancer Institute
National Institutes of Health
Bldg. 10
USA
Name/email consistency: high
- Inhibitors of cyclin-dependent kinase modulators for cancer therapy. Senderowicz, A.M. Prog. Drug. Res (2005)
- Targeting cell cycle and apoptosis for the treatment of human malignancies. Senderowicz, A.M. Curr. Opin. Cell Biol. (2004)
- Novel small molecule cyclin-dependent kinases modulators in human clinical trials. Senderowicz, A.M. Cancer Biol. Ther. (2003)
- Small-molecule cyclin-dependent kinase modulators. Senderowicz, A.M. Oncogene (2003)
- Cell cycle modulators for the treatment of lung malignancies. Senderowicz, A.M. Clin. Lung. Cancer (2003)
- Role of cell cycle control and cyclin-dependent kinases in breast cancer. Senderowicz, A.M. Breast. Dis (2002)
- Preclinical and clinical development of cyclin-dependent kinase modulators. Senderowicz, A.M., Sausville, E.A. J. Natl. Cancer Inst. (2000)
- Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Senderowicz, A.M. Invest. New. Drugs (1999)
- Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. Senderowicz, A.M., Headlee, D., Stinson, S.F., Lush, R.M., Kalil, N., Villalba, L., Hill, K., Steinberg, S.M., Figg, W.D., Tompkins, A., Arbuck, S.G., Sausville, E.A. J. Clin. Oncol. (1998)